Rebucci Chiara, Cerino Antonella, Cividini Agostino, Timo Letizia, Furione Milena, Mondelli Mario U
Laboratori di Ricerca-Area Infettivologica, Servizio di Virologia, IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy.
J Clin Microbiol. 2003 Aug;41(8):3881-4. doi: 10.1128/JCM.41.8.3881-3884.2003.
A recently released immunoassay detecting total serum hepatitis C virus (HCV) core antigen was used to prospectively monitor virological responses to antiviral treatment in patients with chronic HCV infection. Sustained responders cleared core protein from serum within the first month of therapy and maintained stably negative values for the entire duration of follow-up after treatment discontinuation. However, patients who relapsed or failed to respond showed transient negative values and could not be accurately discriminated either because of the intrinsic lower sensitivity of the core-antigen assay than those of molecular assays or because of differentially regulated secretion of immunoreactive core protein from infected hepatocytes.
一种最近发布的检测血清丙型肝炎病毒（HCV）核心抗原总量的免疫测定法被用于前瞻性监测慢性HCV感染患者对抗病毒治疗的病毒学反应。持续应答者在治疗的第一个月内血清中的核心蛋白清除，并且在停药后的整个随访期间维持稳定的阴性值。然而，复发或无反应的患者显示短暂的阴性值，并且由于核心抗原测定法本身比分子测定法敏感性低，或者由于感染肝细胞中免疫反应性核心蛋白的分泌调节不同，无法准确区分。
